Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.40 |
| ▸ | FABP7 | O15540 | 2/20 | 0.40 |
| ▸ | CASP3 | P42574 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | MDM4 | O15151 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL598210 | 0.84 | KMT2A (0.43) | KMT2AFABP5FABP7CASP3CA1 | |
| SCHEMBL29743094 | 0.83 | KMT2A (0.42) | KMT2AFABP5FABP7CASP3CA1 | |
| SCHEMBL29824019 | 0.81 | KMT2A (0.40) | KMT2AFABP5FABP7CASP3CA1 | |
| SCHEMBL29823514 | 0.81 | KMT2A (0.46) | KMT2AFABP5FABP7CASP3CA1 | |
| SCHEMBL29966663 | 0.81 | KMT2A (0.51) | KMT2AFABP5FABP7CASP3CA1 | |
| SCHEMBL15318692 | 0.81 | KMT2A (0.51) | KMT2AFABP5FABP7CASP3CA1 | |
| SCHEMBL29823827 | 0.80 | KMT2A (0.50) | KMT2AFABP5FABP7CASP3CA1 | |
| SCHEMBL14416228 | 0.80 | KMT2A (0.47) | KMT2AFABP5FABP7CASP3CA1 | |
| SCHEMBL29510568 | 0.80 | KMT2A (0.47) | KMT2AFABP5FABP7CASP3CA1 | |
| SCHEMBL16128277 | 0.80 | CASP3 (0.50) | KMT2AFABP5FABP7CASP3CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617819-B2 | Intermediate used for biologically active polypeptide and method for preparing same | HANMI FINE CHEMICAL CO., LTD. (KR) | 2026-05-05 | — | — | US | disclosed |
| US-20220242913-A1 | NOVEL INTERMEDIATE USED FOR BIOLOGICALLY ACTIVE POLYPEPTIDE AND METHOD FOR PREPARING SAME | HANMI FINE CHEMICAL CO., LTD. (KR) | 2022-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220242913-A1 | NOVEL INTERMEDIATE USED FOR BIOLOGICALLY ACTIVE POLYPEPTIDE AND METHOD FOR PREPARING SAME | VIP, IAPP, ANPEP | KMT2A 4831/4885FABP5 1686/4885FABP7 920/4885 |
| US-12617819-B2 | Intermediate used for biologically active polypeptide and method for preparing same | VIP, PTMS, HM13 | KMT2A 3953/4885FABP5 4405/4885FABP7 2486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.